Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02903771 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.
A Phase 1 study, sponsored by Kazia Therapeutics Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT02903771: Completed Phase 1 study, sponsored by Kazia Therapeutics Limited.
NCT02903771 is a Phase 1 study that has completed, run by Kazia Therapeutics Limited. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02903771, a Phase 1 study, has completed, sponsored by Kazia Therapeutics Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine the safety and feasibility of weekly intra-peritoneal administration of Cantrixil to women with persistent or recurrent ovarian cancer, Fallopian tube cancer or primary peritoneal cancer. The study also aims to determine the maximum tolerated dose of Cantrixil in these patients when administered as a monotherapy or a combination therapy.
Primary Outcome
Determination of the MTD: At each dose level, the number and proportion of patients in the MTD population who experience a dose-limiting toxicity (DLT) during the DLT evaluation period (Cycle 1/Part A) of Cantrixil using standard safety monitoring assessments when administered as a monotherapy. The MDT was the dose level below the cohort in which 1 or more patients had experienced a DLT.
Interventions
- DRUG Part A: Dose Escalation of Cantrixil
- DRUG Part B: Expansion Cohort of Cantrixil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2016-12-05 |
| Est. Completion | 2020-03-24 |
| Phase | Phase 1 |
What the finished NCT02903771 record still lists
NCT02903771 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 2 interventions - of which Part A: Dose Escalation of Cantrixil is the first listed.
NCT02903771 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02903771 about?
NCT02903771 is a clinical study titled "Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.". The main purpose of this study is to determine the safety and feasibility of weekly intra-peritoneal administration of Cantrixil to women with persistent or recurrent ovarian cancer, Fallopian tube cancer or primary peritoneal cancer. The study also aims to determine the maximum tolerated dose of Ca...
What is the current status of trial NCT02903771?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2016-12-05. Estimated completion is 2020-03-24.
What interventions are being tested in trial NCT02903771?
The interventions under investigation include: Part A: Dose Escalation of Cantrixil (DRUG), Part B: Expansion Cohort of Cantrixil (DRUG).
Who is sponsoring clinical trial NCT02903771?
This trial is sponsored by Kazia Therapeutics Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02903771's enrollment target sits among peer trials
32 1296th of 2000 higher than 679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI